Articles tagged "Graft survival"

2020 American Transplant Congress
High Intra-Patient Variability of Tacrolimus in Pediatric and Adolescent Renal Transplant Recipients is Associated with Worse Graft Outcomes
K. Piburn¹, L. Maestretti², R. Shetty², M. V. Patton², A. McGrath², W. Concepcion¹, A. Chaudhuri¹, P. C. Grimm¹, V. K. Sigurjonsdottir³
¹Stanford University, Palo Alto, CA, ²Lucile Packard Children's Hospital Stanford, Palo Alto, CA, ³Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
*Purpose: High intra-patient variability (IPV) in tacrolimus (TAC) levels is associated with de novo donor-specific antibodies (dnDSA) and graft loss. We examined the natural history…
2020 American Transplant Congress
Living Donor Liver Transplantation Demonstrated Superiority to Deceased Donor Transplantation after Adult-To-Adult Liver Transplantation in Cumulative Single-Center Retrospective Cohort Study of 19 Years
T. Goto, T. Reichman, G. Sapisochin, I. McGilvray, M. Selzner, A. Ghanekar, M. Cattral, N. Selzner
Multi-Organ Transplant Program, Toronto General Hospital, Institute of Medical Science, University of Toronto, Toronto, ON, Canada
*Purpose: Living donor liver transplantation (LDLT) is an alternative way to deceased donor liver transplantation (DDLT). LDLT and DDLT showed similar short-term outcomes of recipient…
2020 American Transplant Congress
CEACAM1 / ASK1 / p38 Signaling Axis Alleviates Peri-Transplant Liver Injury: From Mouse-to-Human
H. Hirao¹, K. Nakamura², S. Kageyama¹, T. Ito¹, K. Kadono¹, H. Kojima¹, K. J. Dery¹, S. Younan¹, R. W. Busuttil¹, F. M. Kaldas¹, J. Kupiec-Weglinski¹
¹UCLA, Los Angeles, CA, ²Kyoto University, Kyoto, Japan
*Purpose: Although CEACAM1 (CM1; carcinoembryonic antigen-related cell adhesion molecule 1; CD66a) regulates hepatic metabolic homeostasis, its role in orthotopic liver transplantation (OLT) remains unknown. A…
2020 American Transplant Congress
Influence of Human Leukocyte Antigen Status and Gender of Positive Crossmatch Patients on Long-Term Survival Outcomes of Antibody Incompatible Renal Transplantation
N. R. Macha¹, A. Abimbola¹, N. Khovanova², D. Briggs³, N. Krishnan⁴
¹CIRAL, Coventry University, Coventry, United Kingdom, ²School of Engineering, University of Warwick, Warwickshire, United Kingdom, ³Director, Tissue Typing Lab, NHSBT, Birmingham, United Kingdom, ⁴Consultant Transplant Nephrologist and Visiting Professor, CIRAL, University Hospital Coventry & Warwickshire, Coventry, United Kingdom
*Purpose: Human Leukocyte Antigen (HLA) sensitization is a significant obstacle which limits the use of renal transplantation, but it serves as a therapeutic option for…
2020 American Transplant Congress
Clinical Significance of Late Antibody-Mediated Rejection without Donor Specific Anti-hLA Antibodies
J. Lee¹, E. Kim¹, S. Yang¹, S. Kim¹, B. Lim², H. Choi³, B. Kim⁴, B. Kim⁴, M. Ju⁵, M. Kim¹, S. Kim¹, Y. Kim¹, K. Huh¹
¹Department of Transplantation Surgery, Severance Hospital, Seoul, Korea, Republic of, ²Department of Pathology, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Department of Internal Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of, ⁴Department of Internal Medicine, Severance Hospital, Seoul, Korea, Republic of, ⁵Department of Surgery, Gangnam Severance Hospital, Seoul, Korea, Republic of
*Purpose: Late onset antibody-mediated rejection (AMR) is a leading cause of kidney allograft failure. Its diagnosis has been based on a combination of morphologic, immunohistologic…
2020 American Transplant Congress
Cyclophilin-D Inhibition Mitigates Cardiac Allograft Ischemia-Reperfusion Injury and Rejection
A. Qamar¹, P. McLeod², J. Jiang², X. Huang², A. M. Jevnikar², Z. Zhang²
¹Pathology & Laboratory Medicine, University of Western Ontario, London, ON, Canada, ²London Health Sciences Center, London, ON, Canada
*Purpose: The clinical relevance of ischemia-reperfusion injury (IRI) in the context of organ transplantation is well-established. IRI is associated with various forms of programmed cell…
2020 American Transplant Congress
Effect of Cold Ischemia Time on Long-Term Graft Survival of Post-One Year Survivor Deceased Donor Kidney Transplant Recipients
B. Murthy¹, H. Nguyen², A. Rana¹, A. Awan¹, C. Van Buren³, J. Goss¹
¹Baylor College of Medicine, Houston, TX, ²University of Texas Medical Branch, Galveston, TX, ³University of Texas Houston Medical School, Houston, TX
*Purpose: Prolonged cold ischemia time (CIT) is known to adversely affect short-term graft survival among renal allografts. However, its effect on long-term graft survival is…
2020 American Transplant Congress
Long Term Effect of Tacrolimus Conversion to Sirolimus with Prednisone-Free Regimen in Kidney Allograft Outcomes: A Dynamic Analysis of Graft Survival Using Joint Modeling
S. H. Park¹, B. Ho¹, K. Guo¹, L. Zhao², V. Mas³, J. Leventhal⁴, L. Gallon¹
¹Transplant Nephrology, Northwestern University, Chicago, IL, ²Preventive Medicine, Northwestern University, Chicago, IL, ³University of Tennesse, Memphis, TN, ⁴Transplant Surgery, Northwestern University, Chicago, IL
*Purpose: Findings on long-term impacts of the mammalian target of rapamycin inhibitor inhibitors on kidney allograft are scarce and mixed. A joint modeling approach can…
2019 American Transplant Congress
External Validation of the Living Kidney Donor Profile Index (LKDPI) in the Canadian Kidney Transplant Recipient Population
M. Shantier¹, Y. Li¹, M. Ashwin¹, O. Famure¹, S. K. Singh²
¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Toronto, Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: The LKDPI is a risk index which incorporates clinical characteristics of living kidney donors and their recipients to predict the risk of total graft…
2019 American Transplant Congress
Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Interstitial Fibrosis and Tubular Atrophy
G. Gupta¹, D. Kumar¹, M. Raynaud², A. Loupy², J. Chang³, J. Reeve³, P. Sanghi¹, I. Yakubu¹, L. Kamal¹, M. Levy¹, C. Bhati¹, P. Kimball¹, A. King¹, H. Massey¹, P. Halloran³
¹Virginia Commonwealth University, Richmond, VA, ²Paris Transplant Group, Paris, France, ³Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada
*Purpose: Prior studies on the conversion of tacrolimus (Calcineurin Inhibitor; CNI) to belatacept have been limited in scope due to either the absence of, post-conversion…